利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

19 条记录 (耗时 0.013 秒)

    NOVEL COMPOUND FOR TREATMENT OF TUMOR
    2.
    发明申请
    NOVEL COMPOUND FOR TREATMENT OF TUMOR 审中-公开
    用于治疗肿瘤的新型化合物

    公开(公告)号：US20100303893A1

    公开(公告)日：2010-12-02

    申请号：US12161494

    申请日：2007-01-19

    申请人： Yongzhang Luo ,  Hao Zhou ,  Qingxin Lei ,  Guodong Chang

    发明人： Yongzhang Luo ,  Hao Zhou ,  Qingxin Lei ,  Guodong Chang

    IPC分类号： A61K9/127 ,  C12N11/08 ,  A61K38/50 ,  A61K9/14 ,  A61P35/00 ,  A61P35/04

    CPC分类号： C12N9/78 ,  C12N9/96 ,  C12N11/08 ,  C12Y305/03006

    摘要： Specific modifying agent is coupled to an anti-tumor protein on a certain site. It conquers the disadvantages which include high antigenicity, short circulating half-life, nonuniform modified sites, inhomogeneous component, reduced activity and uncontrollable quality of the products prepared by non-specific modifying method. The anti-tumor protein coupled with specific modifying agent can be used for the treatment of tumor and for manufacturing an anti-tumor medicament.

    摘要翻译： 特异性改性剂与特定部位的抗肿瘤蛋白偶联。 它征服了非特异性修饰方法制备的产品高抗原性，短循环半衰期，不均匀改性部位，不均匀成分，活性降低和不可控质量等缺点。 与特异性修饰剂偶联的抗肿瘤蛋白质可用于治疗肿瘤和制造抗肿瘤药物。

    Nucleolin-Mediated Cancer Diagnostics and Therapy
    3.
    发明申请
    Nucleolin-Mediated Cancer Diagnostics and Therapy 审中-公开
    核仁介导的癌症诊断与治疗

    公开(公告)号：US20090191224A1

    公开(公告)日：2009-07-30

    申请号：US12412065

    申请日：2009-03-26

    申请人： Yongzhang Luo ,  Hubing Shi

    发明人： Yongzhang Luo ,  Hubing Shi

    IPC分类号： A61K39/395 ,  C12Q1/68 ,  A61K38/17 ,  A61P35/00

    CPC分类号： C07K16/28 ,  C07K2317/73 ,  C07K2317/76 ,  C07K2317/77 ,  G01N33/57492

    摘要： The present invention provides for diagnostic kits for identifying cancer patients who are more susceptible to cancer therapies employing endostatin and other angiogenesis inhibitors, based upon the discovery that Nucleolin is a specific receptor for Endostatin. In particular, the diagnostic kits include antibody molecules against Nucleolin, DNA or RNA molecules that specifically bind to nucleic acid molecules encoding Nucleolin. The present invention also discloses methods of screening for angiogenesis inhibitors which specifically interact with Nucleolin, and act as angiogenesis inhibitors in an analogous manner as Endostatin. In addition, the present invention discloses methods of inhibiting the proliferation of endothelial cells or angiogenesis of tumor by administering an anti-nucleolin antibody linked to a cytotoxic agent such as tumor necrosis factor alpha to the endothelial cells.

    摘要翻译： 本发明提供了诊断试剂盒，用于基于发现Nucleolin是内皮抑素特异性受体的发现来鉴定对使用内皮抑制素和其他血管生成抑制剂的癌症疗法更敏感的癌症患者。 特别地，诊断试剂盒包括针对Nucleolin的抗体分子，特异性结合编码Nucleolin的核酸分子的DNA或RNA分子。 本发明还公开了筛选与Nucleolin特异性相互作用的血管生成抑制剂的方法，并以与内皮抑素类似的方式起到血管生成抑制剂的作用。 此外，本发明公开了通过向内皮细胞施用与细胞毒性剂如肿瘤坏死因子α连接的抗核蛋白抗体来抑制内皮细胞增殖或肿瘤血管生成的方法。

    CONJUGATE COMPRISING ANGIOSTATION OR ITS FRAGMENT, THE METHOD FOR PRODUCING THE CONJUGATE AND USE THEREOF
    4.
    发明申请
    CONJUGATE COMPRISING ANGIOSTATION OR ITS FRAGMENT, THE METHOD FOR PRODUCING THE CONJUGATE AND USE THEREOF 审中-公开
    包含放射性物质或其碎片的方法，其生产方法和使用方法

    公开(公告)号：US20100184661A1

    公开(公告)日：2010-07-22

    申请号：US12522661

    申请日：2008-01-10

    申请人： Yongzhang Luo ,  Guodong Chang ,  Shuling Yang ,  Lei Gao ,  Yan Fu

    发明人： Yongzhang Luo ,  Guodong Chang ,  Shuling Yang ,  Lei Gao ,  Yan Fu

    IPC分类号： A61K38/17 ,  C07K17/08 ,  A61P35/00 ,  C07K1/00

    CPC分类号： A61K47/60 ,  C12N9/6435 ,  C12Y304/21007

    摘要： The present invention provides an anti-tumor or anti-angiogenesis medicament, the combination or kit containing the medicament, and the method for producing the same. The anti-tumor or anti-angiogenesis medicament contains a conjugate comprising a modifying agent and the angiostatin or its fragments, wherein the conjugate exhibits prolonged in vivo half-life as compared to an unmodified angiostatin or its fragments. The modifying agent is selected from the group consisting of macromolecular polymers, protein molecules or fragments thereof, peptides, small molecules, or chemical substances of any other forms.

    摘要翻译： 本发明提供抗肿瘤或抗血管生成药物，含有该药物的组合物或试剂盒及其制备方法。 抗肿瘤或抗血管生成药物含有包含修饰剂和血管抑素或其片段的缀合物，其中与未修饰的血管抑素或其片段相比，缀合物表现出延长的体内半衰期。 改性剂选自高分子聚合物，蛋白质分子或其片段，肽，小分子或任何其它形式的化学物质。

    Nucleolin-mediated cancer diagnostics and therapy
    5.
    发明申请
    Nucleolin-mediated cancer diagnostics and therapy 审中-公开
    核仁介导的癌症诊断和治疗

    公开(公告)号：US20060258605A1

    公开(公告)日：2006-11-16

    申请号：US11193042

    申请日：2005-07-29

    申请人： Yongzhang Luo ,  Hubing Shi

    发明人： Yongzhang Luo ,  Hubing Shi

    IPC分类号： A61K48/00 ,  A61K39/395

    CPC分类号： C07K16/28 ,  C07K2317/73 ,  C07K2317/76 ,  C07K2317/77 ,  G01N33/57492

    摘要： The present invention provides for diagnostic kits for identifying cancer patients who are more susceptible to cancer therapies employing endostatin and other angiogenesis inhibitors, based upon the discovery that Nucleolin is a specific receptor for Endostatin. In particular, the diagnostic kits include antibody molecules against Nucleolin, DNA or RNA molecules that specifically bind to nucleic acid molecules encoding Nucleolin. The present invention also discloses methods of screening for angiogenesis inhibitors which specifically interact with Nucleolin, and act as angiogenesis inhibitors in an analogous manner as Endostatin. In addition, the present invention discloses methods of inhibiting the proliferation of endothelial cells or angiogenesis of tumor by administering an anti-nucleolin antibody linked to a cytotoxic agent such as tumor necrosis factor alpha to the endothelial cells.

    摘要翻译： 本发明提供了诊断试剂盒，用于基于发现Nucleolin是内皮抑素特异性受体的发现来鉴定对使用内皮抑制素和其他血管生成抑制剂的癌症疗法更敏感的癌症患者。 特别地，诊断试剂盒包括针对Nucleolin的抗体分子，特异性结合编码Nucleolin的核酸分子的DNA或RNA分子。 本发明还公开了筛选与Nucleolin特异性相互作用的血管生成抑制剂的方法，并以与内皮抑素类似的方式起到血管生成抑制剂的作用。 此外，本发明公开了通过向内皮细胞施用与细胞毒性剂如肿瘤坏死因子α连接的抗核蛋白抗体来抑制内皮细胞增殖或肿瘤血管生成的方法。

    CONJUGATE ANGIOSTATION OR ITS FRAGMENT, THE METHOD OF PRODUCING THE CONJUGATE AND USE THEREOF
    9.
    发明申请
    CONJUGATE ANGIOSTATION OR ITS FRAGMENT, THE METHOD OF PRODUCING THE CONJUGATE AND USE THEREOF 审中-公开
    联合攻击或其碎片，生产和使用它们的方法

    公开(公告)号：US20140056966A1

    公开(公告)日：2014-02-27

    申请号：US13488932

    申请日：2012-06-05

    申请人： Yongzhang LUO ,  Guodong Chang ,  Shuling Yang ,  Lei Gao ,  Yan Fu

    发明人： Yongzhang LUO ,  Guodong Chang ,  Shuling Yang ,  Lei Gao ,  Yan Fu

    IPC分类号： A61K47/48

    CPC分类号： A61K47/60 ,  C12N9/6435 ,  C12Y304/21007

    摘要： The present invention provides an anti-tumor or anti-angiogenesis medicament, the combination or kit containing the medicament, and the method for producing the same. The anti-tumor or anti-angiogenesis medicament contains a conjugate comprising a modifying agent and the angiostatin or its fragments, wherein the conjugate exhibits prolonged in vivo half-life as compared to an unmodified angiostatin or its fragments. The modifying agent is selected from the group consisting of macromolecular polymers, protein molecules or fragments thereof, peptides, small molecules, or chemical substances of any other forms.

    摘要翻译： 本发明提供抗肿瘤或抗血管生成药物，含有该药物的组合物或试剂盒及其制备方法。 抗肿瘤或抗血管生成药物含有包含修饰剂和血管抑素或其片段的缀合物，其中与未修饰的血管抑素或其片段相比，缀合物表现出延长的体内半衰期。 改性剂选自高分子聚合物，蛋白质分子或其片段，肽，小分子或任何其它形式的化学物质。

    N-terminal modified recombinant human endostatin and its production
    10.
    发明授权
    N-terminal modified recombinant human endostatin and its production 有权
    N-末端修饰重组人内皮抑素及其生产

    公开(公告)号：US07078485B2

    公开(公告)日：2006-07-18

    申请号：US10313638

    申请日：2002-12-05

    申请人： Yongzhang Luo ,  Bing Zhou ,  Zhuobing Zhang

    发明人： Yongzhang Luo ,  Bing Zhou ,  Zhuobing Zhang

    IPC分类号： C07K1/00 ,  A61K61/00 ,  C12P21/06

    CPC分类号： C07K14/78 ,  A61K38/00 ,  C07K2319/21

    摘要： The invention relates to endostatin protein, in particular, to N-terminal modified recombinant human endostatin (rhEndostatin) proteins which have an additional metal chelating peptide sequence at the N-terminal, the preparation thereof, and methods of modifying the rhEndostatin to improve its stability in vivo and in vitro, and its biological activity. The invention further related to the resulting N-terminal modified rhEndostatin protein, a pharmaceutical composition containing the same, and use of said modified rhEndostatin or its pharmaceutical composition in treating the angiogenesis-related diseases, especially angiogenesis-dependent tumors.

    摘要翻译： 本发明涉及内皮抑素蛋白，特别涉及在N-末端具有额外的金属螯合肽序列的N-末端修饰的重组人内皮抑素（rhEndostatin）蛋白及其制备方法，以及修饰rhEndostatin以改善其稳定性的方法 体内和体外，及其生物活性。 本发明进一步涉及所得N-末端修饰的rhEndostatin蛋白，含有该组合物的药物组合物，以及所述修饰的rhEndostatin或其药物组合物在治疗血管发生相关疾病尤其是血管生成依赖性肿瘤中的用途。